Heard on the Street: Congressional gridlock on Covid-19 funding won’t be a bad thing for vaccine manufacturers, which will charge a higher price in the private market
Congressional gridlock on Covid-19 funding won’t be a bad thing for manufacturers, which will charge a higher price in the private market
As fourth doses of Covid vaccines roll out, some are questioning whether the general population needs them. At the center of this debate are mysterious T-cells. WSJ’s Daniela Hernandez explains T-cells’ role in Covid immunity and how they relate to antibodies. Illustration: Laura KammermannA Food and Drug Administration committee will meet Tuesday to discuss how to move forward with the next generation of vaccines ahead ofadditional funding for the shots—bad news for the U.S.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Secret Subsidies: How the Government is Gifting Free Money to Airlines via Its Carbon MarketUK airlines were allowed to pollute for free and given subsidies via the UK’s flagship scheme to reduce carbon emissions, new study finds.
Read more »
Pfizer says tweaked COVID-19 shots boost omicron protectionPfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.
Read more »
Pfizer says tweaked COVID-19 shots boost omicron protectionPfizer says either an omicron-targeted booster or a combination shot that mixes the original vaccine with omicron protection substantially increases protection.
Read more »
Pfizer says tweaked Covid-19 shots boost omicron protectionThe announcement comes days before an FDA advisory committee meeting to discuss whether to offer updated boosters to Americans this fall.
Read more »
NPR Cookie Consent and Choices
Read more »
Pfizer says Omicron-specific COVID vaccine generates a stronger responseThe news comes in advance of a meeting of a key FDA advisory committee to examine how the composition of COVID-19 vaccines should be modified as the virus continues evolving and vaccine protection wanes.
Read more »